Rituximab Combined With Azathioprine for Relapsed Anti-MDA5 Antibody-Positive Dermatomyositis With Interstitial Lung Disease: A Case Report.
- 1Department of Rheumatology KKR Takamatsu Hospital 4-18 Tenjinmae Takamatsu 760-0018 Kagawa Japan kkr-ta-hp.gr.jp.
Abstract
Background
Antimelanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5(+) DM) is frequently complicated by interstitial lung disease (ILD) and is associated with a high risk of relapse. Optimal management after relapse remains unclear.Case presentation
A 63-year-old woman presented with characteristic cutaneous manifestations of dermatomyositis and ILD without muscle involvement. She was diagnosed with MDA5(+) DM complicated by ILD and initially treated with high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide, resulting in clinical improvement. However, after discontinuation of calcineurin inhibitor therapy due to adverse events, disease relapse occurred, characterized by worsening cutaneous lesions, progression of pulmonary infiltrates, and an increase in anti-MDA5 antibody titers. Subsequently, azathioprine was initiated, and rituximab was administered thereafter. Both clinical and radiological findings improved, and anti-MDA5 antibody titers progressively decreased. Repeated rituximab infusions were followed by stable clinical findings, allowing glucocorticoid tapering without further relapse.Conclusion
This case suggests that rituximab combined with azathioprine may be a therapeutic option for disease control after relapse with MDA5(+) DM-ILD.
Related
- Synergistic Activity of Venetoclax and Rituximab in Multiply Relapsed or Refractory Waldenström Macroglobulinaemia
- FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
- Staged multi-target therapy for anti-MDA5-positive dermatomyositis-associated rapidly progressive interstitial lung disease: a case report.
- Candidate molecular endotypes and dynamic risk prediction in anti-MDA5-positive dermatomyositis-associated interstitial lung disease: a systematic scoping review
- PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA
BibTeX
@article{ozaki2026rituximab,
title = {{Rituximab Combined With Azathioprine for Relapsed Anti-MDA5 Antibody-Positive Dermatomyositis With Interstitial Lung Disease: A Case Report.}},
author = {Hiroki Ozaki and Yuki Inoue},
journal = {Case reports in rheumatology},
year = {2026},
month = oct,
doi = {10.1155/crrh/9772488},
url = {https://europepmc.org/article/MED/42910266},
note = {CC BY},
}
RIS
TY - JOUR
TI - Rituximab Combined With Azathioprine for Relapsed Anti-MDA5 Antibody-Positive Dermatomyositis With Interstitial Lung Disease: A Case Report.
AU - Hiroki Ozaki
AU - Yuki Inoue
PY - 2026
DA - 2026/10/21
JO - Case reports in rheumatology
DO - 10.1155/crrh/9772488
UR - https://europepmc.org/article/MED/42910266
AB - Background Antimelanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (MDA5(+) DM) is frequently complicated by interstitial lung disease (ILD) and is associated with a high risk of relapse. Optimal management after relapse remains unclear.Case presentation A 63-year-old woman presented with characteristic cutaneous manifestations of dermatomyositis and ILD without muscle involvement. She was diagnosed with MDA5(+) DM complicated by ILD and initially treated with high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide, resulting in clinical improvement. However, after discontinuation of calcineurin inhibitor therapy due to adverse events, disease relapse occurred, characterized by worsening cutaneous lesions, progression of pulmonary infiltrates, and an increase in anti-MDA5 antibody titers. Subsequently, azathioprine was initiated, and rituximab was administered thereafter. Both clinical and radiological findings improved, and anti-MDA5 antibody titers progressively decreased. Repeated rituximab infusions were followed by stable clinical findings, allowing glucocorticoid tapering without further relapse.Conclusion This case suggests that rituximab combined with azathioprine may be a therapeutic option for disease control after relapse with MDA5(+) DM-ILD.
SN - 2090-6889
SN - 2090-6897
ER -